Shanghai Lithy One Health Group

Shanghai Lithy One Health Group is a leading Chinese precision medicine company and contract research organization (CRO) specializing in functional diagnostic services and translational oncology. The company is best known for its proprietary Mini-PDX technology, which enables rapid drug sensitivity testing to guide personalized cancer treatment within a clinically relevant timeframe of seven days. Lithy provides a comprehensive suite of services, including Patient-Derived Xenograft (PDX) models, organoids, and cell-derived models, to support pharmaceutical R&D and clinical decision-making. Headquartered in Shanghai, the group operates high-standard laboratories and maintains extensive collaborations with major hospitals and biotechnology firms to advance precision oncology. The company's approach focuses on functional precision medicine, providing a phenotypic complement to genomic profiling.